|
Variable
|
Group
|
No. of patients
|
%
|
|---|
|
(n = 10)
|
|---|
|
Age, years
|
Median
|
52
| |
| |
Range
|
23-60
| |
| |
<50
|
5
|
50
|
| |
≥50
|
5
|
50
|
|
Sex
|
Men
|
7
|
70
|
| |
Women
|
3
|
30
|
|
Race
|
Caucasian
|
10
|
100
|
|
Number of prior therapies
|
Median
|
2
| |
| |
Range
|
0-5
| |
| |
≤2
|
8
|
80
|
| |
>2
|
2
|
20
|
|
Lactate dehydrogenasea
|
≤upper limit of normal
|
9
|
90
|
| |
>upper limit of normal
|
1
|
10
|
|
TNM stage M1c
|
No
|
6
|
60
|
| |
Yes
|
4
|
40
|
|
ECOG PS
|
0
|
5
|
50
|
| |
1
|
5
|
50
|
|
Therapy
|
BRAF inhibitor alone
|
7
|
70
|
| |
MEK inhibitor alone
|
1
|
10
|
| |
BRAF/MEK inhibitor combination
|
2
|
20
|
|
Treatment response
|
Complete response
|
4
|
40
|
| |
Partial response
|
6
|
60
|
- aUpper limit of normal in our institution = 618 IU/L.
- Abbreviations:ECOG Eastern Cooperative Oncology Group, PS Performance Status, TNM tumor, node, metastasis.
